Atom Therapeutics Co., Ltd.

Atom Therapeutics Co., Ltd. is a clinical-stage biotechnology company headquartered in Hangzhou, China, focused on the discovery and development of novel small-molecule drugs for metabolic, inflammatory and cardiovascular diseases. The company's lead asset, ABP-671 (lingdolinurad), is an investigational therapy for chronic gout and hyperuricemia that has advanced into global Phase 2b/3 and Phase 3 clinical trials, including studies in the United States. A second compound, ABP-745, is in Phase 2 clinical development in the US and Australia for acute gout. Additional small-molecule candidates remain in preclinical development. Atom Therapeutics positions itself around a best-in-class strategy: creating molecules intended to be more potent and significantly less toxic than existing marketed drugs, with the goal of bringing safer and more effective medicines to patients worldwide. The company's pipeline is concentrated in gout and hyperuricemia, with a broader interest in inflammatory, metabolic and cardiovascular indications. Since 2012, founder and CEO Dr. William (Dongfang) Shi and his management team have raised nearly US$170 million to advance ABP-671, ABP-745 and other pipeline compounds. The company closed a Series D financing round in October 2023 for approximately US$83 million, led by Kaitai Capital. Atom Therapeutics operates with a global development footprint, running clinical activities in the United States, Australia and other regions, and maintains a US-facing presence through its atomthera.us website and clinical trial recruitment in Cary, North Carolina. The management team combines China- and US-based clinical development experience, including Senior Vice President of Global Business Development Roy J. Wu, Senior Vice President of Clinical Development Ullrich Schwertschlag, Executive Vice President for China Adam (Wenqing) Jin, and Vice Presidents of Clinical Development Min Fang and Lynda Szczech. The company also draws on rheumatology advisors including Kenneth G. Saag, N. Lawrence Edwards and Robert Terkeltaub.

Atom Therapeutics Co., Ltd. is a clinical-stage biotechnology company based in Hangzhou, China, engaged in new drug discovery and development for metabolic, inflammatory and cardiovascular diseases. The company's history is closely tied to its founder, Dr. William (Dongfang) Shi, who has led the organization and its financing efforts since 2012. Over that period, Dr. Shi and his management team raised nearly US$170 million to advance the company's pipeline, including its lead compounds ABP-671 and ABP-745. The company's lead product, ABP-671 (lingdolinurad), is a novel small-molecule compound for chronic gout and hyperuricemia. It has progressed into multicenter Phase 2b/3 clinical trials worldwide, including in the United States, and is described by the company as being in global Phase 3 trials. Completed clinical trials have shown good efficacy, safety and tolerability, and the company states that ABP-671 is more potent and significantly less toxic than existing drugs on the market. A second small molecule, ABP-745, is in Phase 2 clinical trials in the US and Australia for acute gout. Additional small-molecule drugs are in preclinical development. In October 2023, Atom Therapeutics closed its latest financing round, a Series D of approximately US$83 million led by Kaitai Capital. This funding supports the continued advancement of ABP-671 and ABP-745 along with other pipeline compounds. The company maintains a global development footprint, with clinical activities in the United States, Australia and other regions. Its US-facing website, atomthera.us, highlights ongoing clinical trial recruitment, including a study in Cary, North Carolina, evaluating ABP-671 in combination with allopurinol for chronic and acute gout. Atom Therapeutics' stated intention is to bring best-in-class small-molecule drugs to the global market to provide patients worldwide with safer and more effective medicines. The management team combines experience across China and international markets, and the company is supported by scientific advisors in rheumatology.

• Dr. William (Dongfang) Shi and management team begin raising capital to advance pipeline compounds

• ABP-671 advances into global Phase 2b/3 clinical trials for chronic gout and hyperuricemia

• ABP-745 enters Phase 2 clinical trials in the US and Australia for acute gout

• Atom Therapeutics closes approximately $83 million Series D financing led by Kaitai Capital

• Atom Therapeutics recruits participants in Cary, North Carolina for a clinical trial of ABP-671 in combination with allopurinol

Best-in-class small-molecule drugs for metabolic, inflammatory and cardiovascular diseases, with a focus on safer and more effective gout therapies.

• ABP-671 (lingdolinurad)

  Novel small-molecule compound for chronic gout and hyperuricemia; in global Phase 2b/3 and Phase 3 clinical trials.

• ABP-745

  Small-molecule compound for acute gout; in Phase 2 clinical trials in the US and Australia.

• Preclinical small-molecule candidates

  Additional small-molecule drugs in preclinical development for metabolic, inflammatory and cardiovascular diseases.

1. 1Home New - Atom Therapeuticsatomthera.us
2. 2Metabolic Inflammatory Drug Development - Atom Therapeuticsatomthera.us
3. 3Atom Therapeutics Co., Ltd. (China) - Wikidatawikidata.org